New Research on Anatabine's Beneficial Effect on Alzheimer's Disease Presented at Neuroscience 2012Last update: 10/17/2012 10:00:00 AMGLEN ALLEN, Va., Oct. 17, 2012 /PRNewswire via COMTEX/ -- Star Scientific, Inc. (STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that scientists from its research partner, the Roskamp Institute, presented research this week showing that anatabine supplementation reduces the pathology and signs in an animal model of Alzheimer's disease. The findings were presented in New Orleans, Louisiana, at Neuroscience 2012, the 42nd annual meeting of the Society for Neuroscience, as part of a series of presentations by researchers from the Roskamp Institute on supplementation with anatabine, the active ingredient in the Company's Anatabloc® dietary supplement. Neuroscience 2012 is the world's largest and most prestigious scientific meeting dedicated to brain and neurological science, with more than 32,000 neuroscientists from around the world gathering to observe and participate in presentations relating to more than 16,000 new discoveries in science and health. Megha Verma of the Roskamp Institute delivered the poster presentation titled, "Anti-Inflammatory and Amyloid Beta Lowering Properties of Anatabine in a Transgenic Mouse Model of Alzheimer's Disease", in which scientists reported that anatabine treated Alzheimer's mice retained their memory and learning compared to the untreated Alzheimer's mice. Dr. Michael Mullan, President and CEO of the Roskamp Institute, stated, "In examining how anatabine works, the researchers show that key molecules which govern inflammation were deactivated, and this is important because we know that inflammation both promotes and maintains the deterioration of the brain in Alzheimer's disease." Last year, the Company reported the publication of the first peer-reviewed article on the in-vitro and in-vivo activity of anatabine in Alzheimer's Disease in the European Journal of Pharmacology (Paris et al. 2011 Sept 19). This week's presentation in New Orleans expands upon that published work and marks the first time the data have been presented at an international scientific convention. In addition to the research on Alzheimer's disease, earlier in the conference, the Roskamp Institute presented results of research examining the potential benefit of anatabine for alleviating symptoms associated with multiple sclerosis and in helping with recovery from traumatic brain injury. (To view the Company's press releases on these presentations, click here: )
